# US 6,720,181 B1 · Ubiquitin ligases as therapeutic targets

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 6,720,181 B1
- Document ID: US6720181B1
- Status: Granted
- Kind: B1
- Application number: 09/385,219
- Filed: 1999-08-27
- Granted: 2004-04-13
- Earliest claimed: 1998-08-28
- Assignees: New York University
- Inventors: Dah Shiarn Chiaur; Michele Pagano; Esther Latres
- Web page: https://patentgrep.com/patent/US6720181B1

## CPC

- C12N 9/93: {Ligases (6)}
- A61P 35/00: Antineoplastic agents
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/88: Lyases (4.)
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS

## Abstract

The present invention relates to the discovery, identification and characterization of nucleotides that encode novel substrate-targeting subunits of ubiquitin ligases. The invention encompasses nucleotides encoding novel substrate-targeting subunits of ubiquitin ligases: FBP1, FBP2, FBP3, FBP4, FBP5, FBP6, FBP7, FBP8, FBP9, FBP10, FBP11, FBP12, FBP13, FBP14, FBP15, FBP16, FBP17, FBP18, FBP19, FBP20, FBP21, FBP22, FBP23, FBP24, and FBP25, transgenic mice, knock-out mice, host cell expression systems and proteins encoded by the nucleotides of the present invention. The present invention relates to screening assays that use the novel substrate-targeting subunits to identify potential therapeutic agents such as small molecules, compounds or derivatives and analogues of the novel ubiquitin ligases which modulate activity of the novel ubiquitin ligases for the treatment of proliferative and differentiative disorders, such as cancer, major opportunistic infections, immune disorders, certain cardiovascular diseases, and inflammatory disorders. The invention further encompasses therapeutic protocols and pharmaceutical compositions designed to target ubiquitin ligases and their substrates for the treatment of proliferative disorders.

## Claims

### Claim 1

An isolated nucleic acid molecule comprising the nucleotide sequence of SEQ ID NO:5.

### Claim 2

An isolated nucleic acid molecule comprising a nucleotide sequence which encodes a polypeptide comprising the amino acid sequence of SEQ ID NO:6.

### Claim 3

An isolated nucleic acid molecule comprising a contiguous open reading frame which encodes a polypeptide which 1) binds to Skp1 and 2) comprises an amino acid sequence at least 95% identical to the amino acid sequence of SEQ ID NO:6 over the entire length of SEQ ID NO:6, or a complement of a coding or non-coding strand thereof, wherein said polypeptide has ubiquitination activity.

### Claim 4

An isolated nucleic acid molecule comprising a nucleotide sequence which 1) encodes a polypeptide which binds to Skp1, and 2) hybridizes contiguously over its full length to a second nucleic acid molecule consisting of the nucleotide sequence of SEQ ID NO:5, under conditions of incubation at 65° C. in 0.5 M NaHPO4, 7% sodium dodecyl sulfate (SDS), 1 mM EDTA followed by washing in 0.1×SSC/0.1% SDS at 65° C., wherein said polypeptide has ubiquitination activity, and has at least 95% sequence identity to SEQ ID NO:6.

### Claim 5 (depends on 1, 2, 3)

The isolated nucleic acid molecule of any one of claims 1, 2, 3, and 4 which is derived from a mammalian genome.

### Claim 6

A method for detecting the presence of a nucleic acid molecule comprising the contiguous nucleotide sequence of SEQ ID NO:5 in a sample, said method comprising the steps of:
a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes over its full length to a nucleic acid molecule consisting of a nucleotide sequence of SEQ ID NO:5; and
b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample,
wherein if the nucleic acid probe or primer binds to the nucleic acid in the sample, then the nucleic acid molecule is present in the sample.

### Claim 7 (depends on 6)

The method of claim 6, wherein the sample comprises mRNA molecules and is contacted with a nucleic acid probe.

### Claim 8

An isolated nucleic acid molecule comprising a nucleotide sequence which encodes a fusion polypeptide comprising a contiguous amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:5.

### Claim 9 (depends on 1, 2, 3, 4)

The isolated nucleic acid molecule of any one of claims 1, 2, 3, 4, and 8, further comprising a heterologous nucleic acid sequence.

### Claim 10 (depends on 1, 2, 3, 4)

A nucleotide vector comprising the nucleic acid molecule of any one of claims 1, 2, 3, 4, and 8.

### Claim 11 (depends on 1, 2, 3, 4)

An expression vector comprising the nucleic acid molecule of any one of claims 1, 2, 3, 4, and 8, wherein the nucleic acid sequence is operatively associated with a nucleotide regulatory sequence that controls expression of the nucleotide sequence in a host cell.

### Claim 12 (depends on 1, 2, 3, 4)

An isolated host cell comprising the nucleotide sequence of any one of claims 1, 2, 3, 4, and 8, wherein the nucleic acid sequence is operatively associated with a nucleotide regulatory sequence that controls expression of the nucleotide sequence in a the host cell.